Galectin-3 messenger RNA (LGALS3 mRNA) (LGALS3 mRNA)

LGALS3 mRNA is the messenger RNA transcript that encodes the Galectin-3 protein, a member of the beta-galactoside-binding lectin family (UniProt: P17931). Galectin-3 plays a critical role in various biological processes, including cell adhesion, inflammation, and fibrogenesis (NCBI Gene: 3958). Its overexpression is linked to the progression of chronic diseases such as liver fibrosis, heart failure, and cancer (PMID: 31434073). Targeting the LGALS3 mRNA using RNA-based therapeutics like small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) allows for the specific knockdown of Galectin-3 production at the source (PMID: 25650584). This strategy aims to mitigate the pro-fibrotic and pro-inflammatory effects of Galectin-3, offering a potential therapeutic avenue for conditions where traditional protein-targeting inhibitors may be less effective. While many Galectin-3 inhibitors currently in clinical trials are small molecules or carbohydrates targeting the protein, mRNA-directed approaches represent a growing area of precision medicine research (PMID: 32810011). These RNA-targeted therapies can provide sustained suppression of the target protein with high specificity. However, challenges remain regarding the efficient delivery of these nucleic acids to non-hepatic tissues. Overall, LGALS3 mRNA represents a promising target for treating complex fibro-inflammatory diseases.

Other names

LGALS3 transcriptGalectin-3 mRNAMAC-2 mRNAL-31 mRNACBP35 mRNA

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript to prevent translation into Galectin-3 protein.